Compare ClearPoint Neuro Inc (CLPT) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Koninklijke Philips NV — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Koninklijke Philips NV trades at $26.45 (market cap $25.47B). The key difference: Koninklijke Philips NV is far larger — about 53.2× ClearPoint Neuro Inc's market cap, and Koninklijke Philips NV pays a 3.89% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | PHG | |
|---|---|---|
Market Cap | $478.63M | $25.47B |
Sector | Health | Health |
52-Week High | $29.60 | $32.91 |
52-Week Low | $8.66 | $24.11 |
Enterprise Value | $506.63M | $31.74B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
PHG trades at $27.34, down 0.22% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operating cash flow of $1.17B. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships demonstrate innovation momentum.
The stock presents a mixed outlook with 41% analyst buy ratings but bearish technical indicators. Key opportunities include AI healthcare adoption and margin expansion, while risks involve competitive pressures and debt levels. Valuation appears reasonable with P/E of 24.01 and P/S of 1.31, but requires monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
